Get the Stockscreener App
104.83
0.74%
0.77
After Hours:
105.33
0.50
+0.48%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Abbott Laboratories stock is traded at $104.83, with a volume of 6.16M.
It is up +0.74% in the last 24 hours and down -8.65% over the past month.
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
See More
Previous Close:
$104.06
Open:
$105.45
24h Volume:
6.16M
Relative Volume:
0.58
Market Cap:
$182.16B
Revenue:
$44.33B
Net Income/Loss:
$6.50B
P/E Ratio:
28.20
EPS:
3.717
Net Cash Flow:
$7.40B
1W Performance:
-3.37%
1M Performance:
-8.65%
6M Performance:
-21.36%
1Y Performance:
-16.54%
1-Day Range:
$104.25
$105.81
1-Week Range:
$102.41
$109.77
52-Week Range:
$102.41
$139.06
Abbott Laboratories Stock (ABT) Company Profile
Name
Abbott Laboratories
Sector
Industry
Phone
(224) 667-6100
Address
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
104.83 | 180.82B | 44.33B | 6.50B | 7.40B | 3.717 |
SYK
Stryker Corp
|
327.62 | 125.72B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
87.89 | 111.16B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
69.78 | 101.28B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
82.67 | 47.45B | 6.07B | 1.06B | 1.34B | 1.8063 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-10-25 | Initiated | The Benchmark Company | Buy |
| Jul-18-25 | Upgrade | Jefferies | Hold → Buy |
| Jun-16-25 | Initiated | Leerink Partners | Market Perform |
| Oct-08-24 | Initiated | Oppenheimer | Outperform |
| Sep-19-24 | Initiated | Piper Sandler | Overweight |
| Jul-30-24 | Downgrade | Edward Jones | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Jul-21-23 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| May-30-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-20-23 | Reiterated | Barclays | Overweight |
| Apr-20-23 | Reiterated | Bernstein | Outperform |
| Apr-20-23 | Reiterated | JP Morgan | Overweight |
| Apr-20-23 | Reiterated | Raymond James | Outperform |
| Apr-20-23 | Reiterated | UBS | Buy |
| Apr-20-23 | Reiterated | Wolfe Research | Underperform |
| Mar-29-23 | Initiated | UBS | Buy |
| Oct-26-22 | Initiated | Mizuho | Neutral |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jul-06-22 | Initiated | Wolfe Research | Underperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Jan-27-22 | Reiterated | Credit Suisse | Outperform |
| Jan-27-22 | Reiterated | Morgan Stanley | Overweight |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | UBS | Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Oct-27-21 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Oct-14-21 | Initiated | Redburn | Neutral |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Jan-28-21 | Upgrade | BTIG Research | Neutral → Buy |
| Sep-11-20 | Initiated | Wolfe Research | Outperform |
| Jun-01-20 | Downgrade | Goldman | Neutral → Sell |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-13-19 | Reiterated | BofA/Merrill | Buy |
| Feb-07-19 | Reiterated | BofA/Merrill | Buy |
| Jan-02-19 | Downgrade | Citigroup | Neutral → Sell |
| Nov-30-18 | Upgrade | Goldman | Neutral → Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Jun-27-18 | Initiated | Bernstein | Outperform |
| Jan-30-18 | Reiterated | Citigroup | Neutral |
| Jan-25-18 | Reiterated | Stifel | Buy |
| Jan-25-18 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-03-18 | Initiated | Evercore ISI | Outperform |
| Jan-02-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-02-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-19-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-19-17 | Reiterated | Stifel | Buy |
View All
Abbott Laboratories Stock (ABT) Latest News
Why Abbott (ABT) Is Betting $23B on Cancer Screening - MarketWise
Abbott Earnings Preview: What to Expect - Barchart.com
Abbott Laboratories stock faces pressure amid diagnostics slowdown and FreeStyle Libre competition i - AD HOC NEWS
Is It Time To Reconsider Abbott Laboratories (ABT) After Recent Share Price Weakness? - Yahoo Finance
Abbott Proclaim SCS Lawsuit Alleges Stimulator Lead Migration Resulted in Multiple Surgeries - AboutLawsuits.com
Abbott (ABT) Finalizes $21 Billion Exact Sciences (EXAS) Takeover - Blockonomi
Abbott (ABT) Stock Completes $21B Exact Sciences (EXAS) Acquisition - CoinCentral
Top Analyst Reports for Eli Lilly, RTX & Abbott - Yahoo Finance
Abbott Completes $21B Exact Sciences Deal To Expand Cancer Diagnostics - Citeline News & Insights
The Zacks Analyst Blog Highlights Eli Lilly, RTX, Abbott Laboratories, Ohio Valley Banc and Rave Restaurant - Yahoo Finance Singapore
Abbott (ABT) Stock Rated Buy on Strong Diabetes Trial Results - Insider Monkey
What Is Considered a Good Stock Dividend? 2 Healthcare Stocks Fit the Bill. - The Motley Fool
Abbott closes $23 billion deal to buy Madison-based Exact Sciences - Milwaukee Journal Sentinel
SG Americas Securities LLC Sells 102,478 Shares of Abbott Laboratories $ABT - MarketBeat
Nordea Investment Management AB Has $73.97 Million Position in Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories raised prices, prompting sales slump - MSN
E. Ohman J or Asset Management AB Invests $7.72 Million in Abbott Laboratories $ABT - MarketBeat
Dynamic Advisor Solutions LLC Sells 15,282 Shares of Abbott Laboratories $ABT - MarketBeat
Avanza Fonder AB Boosts Stock Position in Abbott Laboratories $ABT - MarketBeat
Assenagon Asset Management S.A. Increases Position in Abbott Laboratories $ABT - MarketBeat
U.S. Medical Nutrition Market Is Going to Boom | Abbott Laboratories • Nestlé Health Science • Danone - openPR.com
Abbott Laboratories stock completes $21 billion Exact Sciences acquisition, eyes diagnostics growth - AD HOC NEWS
Abbott completes acquisition of Exact Sciences - Abbott MediaRoom
Abbott Completes Exact Sciences Acquisition to Transform Global Cancer Diagnostics - geneonline.com
Abbott Expands Healthcare Ecosystem With Exact Sciences Acquisition - Built In Chicago
Exact Sciences Corp stock delisted from Nasdaq after $21 billion Abbott acquisition completion - AD HOC NEWS
Abbott finalizes purchase of Madison-based Exact Sciences - Spectrum News
Abbott closes $21B Exact Sciences deal - Crain's Chicago Business
Abbott Acquires Exact Sciences to Lead Cancer Screening and Diagnostics Market - Minichart
Abbott completes acquisition of Exact Sciences By Investing.com - Investing.com India
Abbott Laboratories (ABT) Completes Acquisition of Exact Sciences - GuruFocus
Abbott Labs acquires Madison’s Exact Sciences for $23 billion - Wisconsin State Journal
Abbott Laboratories stock hits 52-week low at 105.24 USD By Investing.com - Investing.com Canada
Abbott Laboratories stock hits 52-week low at 105.24 USD - Investing.com
Abbott (ABT) Acquires Exact Sciences to Expand Cancer Diagnostics Reach - GuruFocus
Abbott completes $21 billion acquisition of Exact Sciences, delisting EXAS from Nasdaq - Investing.com
Abbott Finalizes Exact Sciences Acquisition, Expands Cancer Diagnostics - TipRanks
Abbott Acquires Exact Sciences, Strengthening Leadership in Cancer Screening - Intellectia AI
Abbott (NYSE: ABT) closes Exact Sciences cancer diagnostics deal - Stock Titan
Cancer screening push: Abbott closes Exact Sciences deal - Stock Titan
Abbott Laboratories Stock Completes $21 Billion Exact Sciences Acquisition, Eyes Cancer Diagnostics - AD HOC NEWS
Teamwork Financial Advisors LLC Has $317,000 Holdings in Abbott Laboratories $ABT - MarketBeat
TABR Capital Management LLC Invests $7.36 Million in Abbott Laboratories $ABT - MarketBeat
Gradient Investments LLC Grows Stock Holdings in Abbott Laboratories $ABT - MarketBeat
ABT Technical Analysis | Trend, Signals & Chart Patterns | ABBOTT LABORATORIES (NYSE:ABT) - ChartMill
Abbott Laboratories Completes Major Acquisition to Bolster Cancer Diagnostics Portfolio - AD HOC NEWS
Assessing Abbott Laboratories (ABT) Valuation After Recent Share Price Weakness - Yahoo Finance
Wealth Enhancement Advisory Services LLC Purchases 134,139 Shares of Abbott Laboratories $ABT - MarketBeat
Tealwood Asset Management Inc. Sells 17,462 Shares of Abbott Laboratories $ABT - MarketBeat
Tealwood Asset Management Inc. Has $1.33 Million Holdings in Abbott Laboratories $ABT - MarketBeat
New England Research & Management Inc. Acquires 13,240 Shares of Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories Stock (ABT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.27%
1.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):